Position in NVS
as of Mar 31, 2026
· filed Apr 29, 2026
Position Value
$14,705,395
+$5,751,015 QoQ
Shares Held
96,271
+48.2% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.52%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026Brooklyn Investment Group holds $115,864,558 across 14 Drug Manufacturers - General names. NVS ranks #3 (12.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
21,894 | $20,137,444 | |
| 2 | JNJ |
Johnson & Johnson
|
72,598 | $17,745,855 | |
| 3 | NVS |
Novartis AG
This page
|
96,271 | $14,705,395 | |
| 4 | ABBV |
AbbVie Inc.
|
63,195 | $13,744,280 | |
| 5 | MRK |
Merck & Co., Inc.
|
85,476 | $10,281,908 | |
| 6 | AMGN |
Amgen Inc
|
24,742 | $8,705,472 | |
| 7 | GSK |
GSK plc
|
121,594 | $6,710,772 | |
| 8 | AZN |
Astrazeneca PLC
|
24,472 | $4,826,367 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14,705,395 | 96,271 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $8,954,380 | 64,948 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $2,760,750 | 21,528 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $2,673,110 | 22,090 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $783,258 | 7,026 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $54,785 | 563 | Shares | Defined | 2025-01-15 | |
| No filing history on record for this holder in this stock. | ||||||